A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

NCT00865111 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Bupropion 150 mg Extended-Released Tablet, single dose
DRUG: Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose

Sponsor

Actavis Inc.